Innovation and Biomarkers in Cancer Drug Development (September 8-9, 2016; Brussels, Belgium)

The Innovation and Biomarkers in Cancer Drug Development meeting will convene September 8-9, 2016 in Brussels, Belgium and will highlight cooperative approaches to cancer drug development with new cancer biomarkers. This meeting is a collaboration between the European Organisation for Research and Treatment of Cancer (EORTC), NCI, the European Medicines Agency (EMA), and the American Association for Cancer Research (AACR). Registration opens April 12, 2016. The meeting can be followed on Twitter #IBCD2016.

Several DCTD staff have been involved in the planning and implementation of this conference, including the following:

Robert J. Kinders, PhD, Frederick National Laboratory for Cancer Research/Office of the Director
Speaker

Tracy Lively, PhD, Cancer Diagnosis Program
Organizing Committee/Session Chair

Shakun Malik, MD, Cancer Therapy Evaluation Program
Scientific Committee/Session Chair/Speaker

Tawnya McKee, PhD, Cancer Diagnosis Program
Scientific Committee/Session Chair

Helen Moore, PhD, Cancer Diagnosis Program
Scientific Committee/Session Chair

Jeff Moscow, MD, Cancer Therapy Evaluation Program
Scientific Committee/Session Chair